Notice to Our Patients Regarding a Stolen Briefcase. Learn More
Find a Doctor
Hany Elmariah, MD, MS
Specialty: Blood and Marrow Transplant and Cellular Immunotherapy
Program: Blood and Marrow Transplant and Cellular Immunotherapy
Locations: Moffitt Cancer Center
Cancer Focus: Leukemia , MDS, Myelodysplastic Syndromes (MDS)
Dr. Hany Elmariah is an Assistant Member in the Department of Blood and Marrow Transplant and Cellular Immunotherapy. Dr. Elmariah earned his MD and his MS in Biomedical Engineering at the University of Florida. He completed an Internal Medicine Residency at Duke University. Dr. Elmariah recently completed a Hematology and Oncology Fellowship at Johns Hopkins University, where he also served as Chief Fellow. Dr. Elmariah’s clinical interests focus on transplantation as a curative therapy for hematologic malignancies, particularly leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms (myelofibrosis, chronic myelomonocytic leukemia, chronic myelogenous leukemia). Dr. Elmariah’s research is primarily focused on haploidentical donor blood and marrow transplantation as a strategy to increase donor availability for patients in need of blood or marrow transplantation. He also has an interest in novel cellular therapies as potential cures for myeloid malignancies.
Education & Training
- Johns Hopkins Hospital - Hematology and Oncology
- Duke University Medical Center - Internal Medicine
- University of Florida College of MedicineMD
CLINICAL TRIAL 20041
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Condition: Malignant Hematology
Intervention: Cellcept (Mycophenolate Mofetil); FK506 (Tacrolimus); Mycophenolate Mofetil (); Tacrolimus (); cyclophosphamide (); cytoxan (cyclophosphamide); methotrexate ()
CLINICAL TRIAL 20131
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); Cellcept (Mycophenolate Mofetil); FK506 (Tacrolimus); G-CSF (); Melphalan (); Mycophenolate Mofetil (); Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus (); Tacrolimus (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
- DeZern AE, Elmariah H, Zahurak M, Rosner GL, Gladstone DE, Ali SA, Huff CA, Swinnen LJ, Imus P, Borrello I, Wagner-Johnston ND, Ambinder RF, Brodsky RA, Cooke K, Luznik L, Fuchs EJ, Bolaños-Meade J, Jones RJ. Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. Biol Blood Marrow Tr. 2020 Aug. Pubmedid: 32818556.
- Balaji A, Zhang J, Wills B, Marrone KA, Elmariah H, Yarchoan M, Zimmerman JW, Hajjir K, Venkatraman D, Armstrong DK, Laheru DA, Mehra R, Ho WJ, Reuss JE, Heng J, Vellanki P, Donehower RC, Holdhoff M, Naidoo J. Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. J Oncol Pract. 2019 Sep.15(9):e825-e834. Pubmedid: 31386608. Pmcid: PMC6743220.
- Elmariah H, DeZern AE. Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment. Curr Hematol Malig Rep. 2019 Jun.14(3):154-163. Pubmedid: 31093889.
- Elmariah H, Fuchs EJ. Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results. Semin Hematol. 2019 Jul.56(3):183-189. Pubmedid: 31202428.
- Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, Bolaños-Meade J, Fuchs EJ, Wagner-Johnston N, Swinnen LJ, Huff CA, Matsui WH, Gladstone DE, McCurdy SR, Borrello I, Gocke CB, Shanbhag S, Cooke KR, Ali SA, Brodsky RA, DeZern AE, Luznik L, Jones RJ, Ambinder RF. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. Biol Blood Marrow Tr. 2018 May.24(5):1099-1102. Pubmedid: 29452245. Pmcid: PMC6439277.
- Elmariah H, Shanbhag S. Pan-pseudothrombocytopenia: An unusual case of platelet clumping. Am J Hematol. 2018 Jan. Pubmedid: 29341241.
- Elmariah H, Thomas S, Boggan JC, Zaas A, Bae J. The Burden of Burnout. Am J Med Qual. 2017 Mar;32(2):156-162. Pubmedid: 26917807.
- Elmariah H, Pratz KW. Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia. J Natl Compr Canc Ne. 2017 Jul;15(7):959-966. Pubmedid: 28687582.
- Elmariah H, Garrett ME, De Castro LM, Jonassaint JC, Ataga KI, Eckman JR, Ashley-Koch AE, Telen MJ. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014 May;89(5):530-535. Pubmedid: 24478166. Pmcid: PMC3988218.
- Rajasekhar A, Elmariah H, Lottenberg L, Beyth R, Lottenberg R, Ang D. Inferior vena cava filters in trauma patients: a national practice patterns survey of U.S. Trauma centers. Am Surg. 2014 Dec;80(12):1237-1244. Pubmedid: 25513923.
- Welch DE, Elmariah H, Peden MC, Adams SG, Ratnakaram R, Kaushal S. Short-term response of macular oedema to intravitreal bevacizumab. Br J Ophthalmol. 2009 Aug;93(8):1033-1036. Pubmedid: 19403519.
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.Learn more about our patient comments
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
- The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
- He or she may be a researcher or other type of provider that does not see patients.
- The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.